Historique
Article de Périodique
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe (2018)
Auteur(s) :
H. FRASER ;
N. K. MARTIN ;
H. BRUMMER-KORVENKONTIO ;
P. CARRIERI ;
O. DALGARD ;
J. DILLON ;
D. GOLDBERG ;
S. HUTCHINSON ;
M. JAUFFRET-ROUSTIDE ;
M. KABERG ;
A. A. MATSER ;
M. MATICIC ;
H. MIDGARD ;
V. MRAVCIK ;
A. OVREHUS ;
M. PRINS ;
J. REIMER ;
G. ROBAEYS ;
B. SCHULTE ;
D. K. VAN SANTEN ;
R. ZIMMERMANN ;
P. VICKERMAN ;
M. HICKMAN
Article en page(s) :
402-411
Refs biblio. :
49
Domaine :
Drogues illicites / Illicit drugs
Langue(s) :
Anglais
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Thésaurus mots-clés
PRODUIT ILLICITE
;
HEPATITE
;
USAGER
;
INJECTION
;
TRAITEMENT
;
PREVENTION
;
PREVALENCE
;
MODELE
;
INCIDENCE
Note générale :
Editorial: Achieving hepatitis C elimination in Europe - To treatment scale-up and beyond. Hellard M., Scott N., Sacks-Davis R., Pedrana A., p. 383-385.
Résumé :
BACKGROUND & AIMS: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opioid substitution therapy (OST) and needle and syringe programmes (NSPs) across Europe over the next 10years.
METHODS: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings. We parameterised an HCV transmission model to setting-specific data that project chronic HCV prevalence and incidence among PWID.
RESULTS: At baseline, chronic HCV prevalence varied from 55% (Finland/Sweden), and CONCLUSIONS: The scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe.
LAY SUMMARY: Measuring the amount of HCV in the population of PWID is uncertain. To reduce HCV infection to minimal levels in Europe will require scale-up of both HCV treatment and other interventions that reduce injecting risk (especially OST and provision of sterile injecting equipment).
Highlights:
Chronic HCV prevalence and treatment rates among PWID vary widely across Europe.
HCV treatment scale-up is required in most sites to reduce HCV transmission.
Increasing OST/NSP coverage enhances HCV treatment prevention benefit.
METHODS: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings. We parameterised an HCV transmission model to setting-specific data that project chronic HCV prevalence and incidence among PWID.
RESULTS: At baseline, chronic HCV prevalence varied from 55% (Finland/Sweden), and CONCLUSIONS: The scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe.
LAY SUMMARY: Measuring the amount of HCV in the population of PWID is uncertain. To reduce HCV infection to minimal levels in Europe will require scale-up of both HCV treatment and other interventions that reduce injecting risk (especially OST and provision of sterile injecting equipment).
Highlights:
Chronic HCV prevalence and treatment rates among PWID vary widely across Europe.
HCV treatment scale-up is required in most sites to reduce HCV transmission.
Increasing OST/NSP coverage enhances HCV treatment prevention benefit.
Affiliation :
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
Autre(s) lien(s) :
Editorial